Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Oct 15;98(8):1794–1801. doi: 10.1172/JCI118979

Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission.

J Townsley-Fuchs 1, L Kam 1, R Fairhurst 1, S J Gange 1, L Goodglick 1, J V Giorgi 1, N Sidell 1, R Detels 1, J Braun 1
PMCID: PMC507618  PMID: 8878430

Abstract

HIV-1 gp120 is an immunoglobulin superantigen which can bind to preimmune serum Ig. We hypothesize that levels of such preimmune antibodies vary in the population and might affect host resistance or susceptibility to viral transmission. This study tests two predictions: (a) levels of preimmune anti-gpl20 Igs are a polymorphic trait; and, (b) these levels are correlated with resistance or susceptibility to HIV-1 transmission. The first prediction was confirmed in a longitudinal study of a low-risk seronegative population. In this group, levels of both endogenous anti-gpl20 IgM and IgG varied widely, but were characteristic and stable for each individual. The second prediction was addressed in a study of participants of the Multicenter AIDS Cohort Study, in which men "susceptible" and "resistant" to HIV infection were identified based on numbers of sexual partners and eventual seroconversion. Specimens consisted of archival sera obtained > 2 yr before seroconversion. Men in the susceptible population (low-risk seroconverters) were distinguished by low levels of anti-gpl20 IgG. We conclude that the level of preimmune anti-gpl20 IgG is a polymorphic population trait, and low levels are a potentially specific and significant factor in homosexual transmission of HIV infection.

Full Text

The Full Text of this article is available as a PDF (215.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berberian L., Goodglick L., Kipps T. J., Braun J. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science. 1993 Sep 17;261(5128):1588–1591. doi: 10.1126/science.7690497. [DOI] [PubMed] [Google Scholar]
  2. Berberian L., Shukla J., Jefferis R., Braun J. Effects of HIV infection on VH3 (D12 idiotope) B cells in vivo. J Acquir Immune Defic Syndr. 1994 Jul;7(7):641–646. [PubMed] [Google Scholar]
  3. Berberian L., Valles-Ayoub Y., Sun N., Martinez-Maza O., Braun J. A VH clonal deficit in human immunodeficiency virus-positive individuals reflects a B-cell maturational arrest. Blood. 1991 Jul 1;78(1):175–179. [PubMed] [Google Scholar]
  4. Burke D. S. Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk? Perspect Biol Med. 1992 Summer;35(4):511–530. doi: 10.1353/pbm.1992.0048. [DOI] [PubMed] [Google Scholar]
  5. Burton D. R., Pyati J., Koduri R., Sharp S. J., Thornton G. B., Parren P. W., Sawyer L. S., Hendry R. M., Dunlop N., Nara P. L. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994 Nov 11;266(5187):1024–1027. doi: 10.1126/science.7973652. [DOI] [PubMed] [Google Scholar]
  6. Casali P., Notkins A. L. Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes. Annu Rev Immunol. 1989;7:513–535. doi: 10.1146/annurev.iy.07.040189.002501. [DOI] [PubMed] [Google Scholar]
  7. Clarke S. H., Staudt L. M., Kavaler J., Schwartz D., Gerhard W. U., Weigert M. G. V region gene usage and somatic mutation in the primary and secondary responses to influenza virus hemagglutinin. J Immunol. 1990 Apr 1;144(7):2795–2801. [PubMed] [Google Scholar]
  8. Detels R., Liu Z., Hennessey K., Kan J., Visscher B. R., Taylor J. M., Hoover D. R., Rinaldo C. R., Jr, Phair J. P., Saah A. J. Resistance to HIV-1 infection. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1994 Dec;7(12):1263–1269. [PubMed] [Google Scholar]
  9. Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992 Feb 20;355(6362):728–730. doi: 10.1038/355728a0. [DOI] [PubMed] [Google Scholar]
  10. Fish S., Zenowich E., Fleming M., Manser T. Molecular analysis of original antigenic sin. I. Clonal selection, somatic mutation, and isotype switching during a memory B cell response. J Exp Med. 1989 Oct 1;170(4):1191–1209. doi: 10.1084/jem.170.4.1191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goodglick L., Braun J. Revenge of the microbes. Superantigens of the T and B cell lineage. Am J Pathol. 1994 Apr;144(4):623–636. [PMC free article] [PubMed] [Google Scholar]
  12. Goodglick L., Zevit N., Neshat M. S., Braun J. Mapping the Ig superantigen-binding site of HIV-1 gp120. J Immunol. 1995 Dec 1;155(11):5151–5159. [PubMed] [Google Scholar]
  13. Grandien A., Fucs R., Nobrega A., Andersson J., Coutinho A. Negative selection of multireactive B cell clones in normal adult mice. Eur J Immunol. 1994 Jun;24(6):1345–1352. doi: 10.1002/eji.1830240616. [DOI] [PubMed] [Google Scholar]
  14. Greenspan N. S., Cooper L. J. Complementarity, specificity and the nature of epitopes and paratopes in multivalent interactions. Immunol Today. 1995 May;16(5):226–230. doi: 10.1016/0167-5699(95)80164-2. [DOI] [PubMed] [Google Scholar]
  15. Hillson J. L., Oppliger I. R., Sasso E. H., Milner E. C., Wener M. H. Emerging human B cell repertoire. Influence of developmental stage and interindividual variation. J Immunol. 1992 Dec 1;149(11):3741–3752. [PubMed] [Google Scholar]
  16. Jiang S. B., Lin K., Neurath A. R. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J Exp Med. 1991 Dec 1;174(6):1557–1563. doi: 10.1084/jem.174.6.1557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Joling P., Bakker L. J., Van Strijp J. A., Meerloo T., de Graaf L., Dekker M. E., Goudsmit J., Verhoef J., Schuurman H. J. Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol. 1993 Feb 1;150(3):1065–1073. [PubMed] [Google Scholar]
  18. Koziol D. E., Saah A. J., Odaka N., Muñoz A. A comparison of risk factors for human immunodeficiency virus and hepatitis B virus infections in homosexual men. Ann Epidemiol. 1993 Jul;3(4):434–441. doi: 10.1016/1047-2797(93)90073-d. [DOI] [PubMed] [Google Scholar]
  19. Kozlowski P. A., Black K. P., Shen L., Jackson S. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG. J Immunol. 1995 Jun 1;154(11):6163–6173. [PubMed] [Google Scholar]
  20. Law C. L., Qassim M., Cunningham A. L., Mulhall B., Grierson J. M. Nonspecific proctitis: association with human immunodeficiency virus infection in homosexual men. J Infect Dis. 1992 Jan;165(1):150–154. doi: 10.1093/infdis/165.1.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lederman M. M., Jackson J. B., Kroner B. L., White G. C., 3rd, Eyster M. E., Aledort L. M., Hilgartner M. W., Kessler C. M., Cohen A. R., Kiger K. P. Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacs. J Infect Dis. 1995 Jul;172(1):228–231. doi: 10.1093/infdis/172.1.228. [DOI] [PubMed] [Google Scholar]
  22. Lee T. H., Sheppard H. W., Reis M., Dondero D., Osmond D., Busch M. P. Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. J Acquir Immune Defic Syndr. 1994 Apr;7(4):381–388. [PubMed] [Google Scholar]
  23. Levy J. A. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 1993 Mar;57(1):183–289. doi: 10.1128/mr.57.1.183-289.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Marthas M. L., van Rompay K. K., Otsyula M., Miller C. J., Canfield D. R., Pedersen N. C., McChesney M. B. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol. 1995 Jul;69(7):4198–4205. doi: 10.1128/jvi.69.7.4198-4205.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Miller C. J., McGhee J. R., Gardner M. B. Mucosal immunity, HIV transmission, and AIDS. Lab Invest. 1993 Feb;68(2):129–145. [PubMed] [Google Scholar]
  26. Miller C. J., McGhee J. R., Gardner M. B. Mucosal immunity, HIV transmission, and AIDS. Lab Invest. 1993 Feb;68(2):129–145. [PubMed] [Google Scholar]
  27. Olee T., Yang P. M., Siminovitch K. A., Olsen N. J., Hillson J., Wu J., Kozin F., Carson D. A., Chen P. P. Molecular basis of an autoantibody-associated restriction fragment length polymorphism that confers susceptibility to autoimmune diseases. J Clin Invest. 1991 Jul;88(1):193–203. doi: 10.1172/JCI115277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pantaleo G., Demarest J. F., Soudeyns H., Graziosi C., Denis F., Adelsberger J. W., Borrow P., Saag M. S., Shaw G. M., Sekaly R. P. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature. 1994 Aug 11;370(6489):463–467. doi: 10.1038/370463a0. [DOI] [PubMed] [Google Scholar]
  29. Pantaleo G., Graziosi C., Fauci A. S. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993 Feb 4;328(5):327–335. doi: 10.1056/NEJM199302043280508. [DOI] [PubMed] [Google Scholar]
  30. Pascual V., Capra J. D. B-cell superantigens? Curr Biol. 1991 Oct;1(5):315–317. doi: 10.1016/0960-9822(91)90097-g. [DOI] [PubMed] [Google Scholar]
  31. Press J. L., Giorgetti C. A. Molecular and kinetic analysis of an epitope-specific shift in the B cell memory response to a multideterminant antigen. J Immunol. 1993 Aug 15;151(4):1998–2013. [PubMed] [Google Scholar]
  32. Prince A. M., Reesink H., Pascual D., Horowitz B., Hewlett I., Murthy K. K., Cobb K. E., Eichberg J. W. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses. 1991 Dec;7(12):971–973. doi: 10.1089/aid.1991.7.971. [DOI] [PubMed] [Google Scholar]
  33. Robert-Guroff M., Roilides E., Muldoon R., Venzon D., Husson R., Marshall D., Gallo R. C., Pizzo P. A. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value. J Infect Dis. 1993 Mar;167(3):538–546. doi: 10.1093/infdis/167.3.538. [DOI] [PubMed] [Google Scholar]
  34. Rutherford G. W. Long-term survival in HIV-1 infection. BMJ. 1994 Jul 30;309(6950):283–284. doi: 10.1136/bmj.309.6950.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Saarloos M. N., Lint T. F., Spear G. T. Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells. Clin Exp Immunol. 1995 Feb;99(2):189–195. doi: 10.1111/j.1365-2249.1995.tb05531.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sasso E. H., Silverman G. J., Mannik M. Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup. J Immunol. 1991 Sep 15;147(6):1877–1883. [PubMed] [Google Scholar]
  37. Sasso E. H., Willems van Dijk K., Bull A., van der Maarel S. M., Milner E. C. VH genes in tandem array comprise a repeated germline motif. J Immunol. 1992 Aug 15;149(4):1230–1236. [PubMed] [Google Scholar]
  38. Saxon A., Keld B., Braun J., Dotson A., Sidell N. Long-term administration of 13-cis retinoic acid in common variable immunodeficiency: circulating interleukin-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production. Immunology. 1993 Nov;80(3):477–487. [PMC free article] [PubMed] [Google Scholar]
  39. Silverman G. J., Lucas A. H. Variable region diversity in human circulating antibodies specific for the capsular polysaccharide of Haemophilus influenzae type b. Preferential usage of two types of VH3 heavy chains. J Clin Invest. 1991 Sep;88(3):911–920. doi: 10.1172/JCI115394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Silverman G. J., Sasano M., Wormsley S. B. Age-associated changes in binding of human B lymphocytes to a VH3-restricted unconventional bacterial antigen. J Immunol. 1993 Nov 15;151(10):5840–5855. [PubMed] [Google Scholar]
  41. Stewart A. K., Huang C., Stollar B. D., Schwartz R. S. High-frequency representation of a single VH gene in the expressed human B cell repertoire. J Exp Med. 1993 Feb 1;177(2):409–418. doi: 10.1084/jem.177.2.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Süsal C., Kirschfink M., Kröpelin M., Daniel V., Opelz G. Complement activation by recombinant HIV-1 glycoprotein gp120. J Immunol. 1994 Jun 15;152(12):6028–6034. [PubMed] [Google Scholar]
  43. Thieblemont N., Haeffner-Cavaillon N., Weiss L., Maillet F., Kazatchkine M. D. Complement activation by gp160 glycoprotein of HIV-1. AIDS Res Hum Retroviruses. 1993 Mar;9(3):229–233. doi: 10.1089/aid.1993.9.229. [DOI] [PubMed] [Google Scholar]
  44. Torian L. V., Weisfuse I. B., Makki H. A., Benson D. A., DiCamillo L. M., Toribio F. E. Increasing HIV-1 seroprevalence associated with genital ulcer disease, New York City, 1990-1992. AIDS. 1995 Feb;9(2):177–181. [PubMed] [Google Scholar]
  45. Zolla-Pazner S., Gorny M. K. Passive immunization for the prevention and treatment of HIV infection. AIDS. 1992 Nov;6(11):1235–1247. doi: 10.1097/00002030-199211000-00001. [DOI] [PubMed] [Google Scholar]
  46. Zouali M. B-cell superantigens: implications for selection of the human antibody repertoire. Immunol Today. 1995 Aug;16(8):399–405. doi: 10.1016/0167-5699(95)80009-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES